Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common heart pill slow Parkinson's? small trial aims to find out

NCT ID NCT04218968

Disease control Sponsor: Cedars-Sinai Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether carvedilol, a drug usually used for heart conditions, can slow the loss of dopamine transporters in the brain and delay Parkinson's symptoms. It follows 15 people with REM sleep behavior disorder and other early Parkinson's risk factors over three years. Researchers will use brain scans and clinical checks to see if the drug reduces the rate of decline.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Carvedilol (a heart medication that blocks adrenergic signals)
What this could lead to
If it works, this could point toward a way to slow Parkinson's disease progression in people with early warning signs.
What could go wrong
This is a very small, early-phase study with only 15 participants. It may not show a clear benefit, and carvedilol is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2019

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Enrolled in the study "The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease" (Pro#00053136) * Capacity to give informed consent Exclusion Criteria: * Secondary Parkinsonism, including tardive * Concurrent dementia defined by a score lower than 22 on the MoCA * Concurrent severe depression defined by a BDI fast screen score greater than 13 * Comorbidities related to SNS hyperactivity * Heart failure (LVEF \<45%) * Recent myocardial revascularization (\<12 weeks) * Hypertension (SBP\>150mmHg or DBP\>100mmHg) * Chronic Atrial fibrillation * Concurrent Use of Beta-adrenergic antagonist * Diabetes mellitus * COPD * Untreated Sever Sleep Apnea; Apnea-Hypopnea Index (AHI) \> 30/h. * Severely reduced kidney function (Glomerular Filtration Rate\<30ml/min) * Contraindications to the use of carvedilol * Asthma or bronchospasm * Recent myocardial infarction (\<48 h) * Ongoing unstable angina * Cardiogenic shock or prolonged hypotension * Second or Third-Degree AV block * Significant valvular aortic stenosis * Obstructive cardiomyopathy, or constrictive pericarditis * Resting Heart Rate (RHR)\< 45 Or Bradycardia (HR\<60) with at least one of the following symptoms; Lightheadedness, dizziness, weakness, Altered mental status, Shortness of breath, Pre-Syncope, Syncope, Sick Sinus Syndrome, Stroke within the past 1 month, Severe Hepatic Dysfunction * Allergy/hypersensitivity to iodine or study medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre-motor Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease REM sleep behavior disorder secondary Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pre-motor Parkinson disease Rem sleep behavior disorder Symptomatic Parkinson disease

Contacts and locations

Locations

  • Michele L Lima Gregorio

    Los Angeles, California, 90046, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.